Home LiteratureArticle Details
PMID: 22451929 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Decade-long bacterial community dynamics in cystic fibrosis airways.

Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ

Abstract

The structure and dynamics of bacterial communities in the airways of persons with cystic fibrosis (CF) remain largely unknown. We characterized the bacterial communities in 126 sputum samples representing serial collections spanning 8-9 y from six age-matched male CF patients. Sputum DNA was analyzed by bar-coded pyrosequencing of the V3-V5 hypervariable region of the 16S rRNA gene, defining 662 operational taxonomic units (OTUs) from >633,000 sequences. Bacterial community diversity decreased significantly over time in patients with typically progressive lung disease but remained relatively stable in patients with a mild lung disease phenotype. Antibiotic use, rather than patient age or lung function, was the primary driver of decreasing diversity. Interpatient variability in community structure exceeded intrapatient variability in serial samples. Antibiotic treatment was associated with pronounced shifts in community structure, but communities showed both short- and long-term resilience after antibiotic perturbation. There was a positive correlation between OTU occurrence and relative abundance, with a small number of persistent OTUs accounting for the greatest abundance. Significant changes in community structure, diversity, or total bacterial density at the time of pulmonary exacerbation were not observed. Despite decreasing community diversity in patients with progressive disease, total bacterial density remained relatively stable over time. These findings show the critical relationship between airway bacterial community structure, disease stage, and clinical state at the time of sample collection. These features are the key parameters with which to assess the complex ecology of the CF airway.

MeSH Terms
Adolescent Adult Aging/drug effects Anti-Bacterial Agents/pharmacology,therapeutic use Bacteria/classification,drug effects,growth & development Bacterial Load/drug effects Biodiversity Cystic Fibrosis/drug therapy,microbiology,physiopathology Disease Progression Humans Lung/drug effects,microbiology,pathology,physiopathology Male Metagenome/drug effects Principal Component Analysis Respiratory Function Tests Sputum/drug effects,microbiology Young Adult
Chemicals
Anti-Bacterial Agents
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Zhao Jiangchao
Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Schloss Patrick D
Kalikin Linda M
Carmody Lisa A
Foster Bridget K
Petrosino Joseph F
Cavalcoli James D
VanDevanter Donald R
Murray Susan
Li Jun Z
Young Vincent B
LiPuma John J
References (16)
16 references, click to expand
  1. Lung infections in cystic fibrosis: deriving clinical insight from microbial complexity.
    Expert Rev Mol Diagn. 2010 Mar;10(2):187-96 PMID: 20214537
  2. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.
    Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15070-5 PMID: 18812504
  3. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities.
    ISME J. 2011 May;5(5):780-91 PMID: 21151003
  4. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set.
    Microbiology (Reading). 2002 Jan;148(Pt 1):257-266 PMID: 11782518
  5. Impact of enhanced Staphylococcus DNA extraction on microbial community measures in cystic fibrosis sputum.
    PLoS One. 2012;7(3):e33127 PMID: 22412992
  6. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.
    PLoS One. 2010 Jun 23;5(6):e11044 PMID: 20585638
  7. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data.
    Am J Respir Crit Care Med. 2006 Oct 1;174(7):780-6 PMID: 16858011
  8. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis.
    ISME J. 2011 Jan;5(1):20-9 PMID: 20631810
  9. Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections.
    Diagn Microbiol Infect Dis. 2008 Oct;62(2):133-41 PMID: 18692341
  10. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.
    Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20529-33 PMID: 18077362
  11. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.
    Appl Environ Microbiol. 2009 Dec;75(23):7537-41 PMID: 19801464
  12. Characterizing aggressiveness and predicting future progression of CF lung disease.
    J Cyst Fibros. 2009 Jun;8 Suppl 1:S15-9 PMID: 19460682
  13. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Environ Microbiol. 2010 May;12(5):1293-303 PMID: 20192960
  14. characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling.
    J Clin Microbiol. 2004 Nov;42(11):5176-83 PMID: 15528712
  15. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?
    J Cyst Fibros. 2011 Sep;10(5):357-65 PMID: 21664196
  16. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
    Am J Respir Crit Care Med. 2008 May 1;177(9):995-1001 PMID: 18263800
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2012-04-10
Epub
2012-00-26
Pages
5809-14
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC3326496
Subset
IM
Grants
NIDDK NIH HHS · P30DK034933 · United States
NIDDK NIH HHS · P30 DK027651 · United States
NCRR NIH HHS · UL1RR024986 · United States
NHGRI NIH HHS · R01HG004906 · United States
NIDDK NIH HHS · P30 DK034933 · United States
NHLBI NIH HHS · RC1 HL100809 · United States
NHGRI NIH HHS · R01 HG004906 · United States
NHLBI NIH HHS · 1RC1HL100809-01 · United States
NCRR NIH HHS · UL1 RR024986 · United States
NHGRI NIH HHS · R01 HG005975 · United States
NHGRI NIH HHS · 1R01HG005975-01 · United States
NHLBI NIH HHS · U01 HL098961 · United States
NHLBI NIH HHS · U01HL098961 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com